|Bid||556.00 x 1800|
|Ask||559.01 x 800|
|Day's Range||556.47 - 564.87|
|52 Week Range||337.80 - 572.96|
|PE Ratio (TTM)||82.11|
|Earnings Date||Oct 17, 2018 - Oct 22, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||569.80|
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
SANTA BARBARA, Calif., Sept. 20, 2018 /PRNewswire/ -- InTouch Health, the leading enterprise telehealth platform, today announced it has signed a multi-year licensing service agreement with Intuitive Surgical, Inc. (ISRG), the pioneer and a global technology leader in robotic-assisted, minimally invasive surgery. Under the agreement, the two companies will collaborate to deepen Intuitive's Internet of Medical Things (IoMT) network to connect into thousands of da Vinci surgical systems in medical institutions around the world on a single global network. InTouch Health's proprietary IoMT network will enable healthcare companies like Intuitive, to connect directly to their surgical systems worldwide to exchange real-time data for enhanced clinical insights, proactive service and maintenance monitoring, surgical collaboration between disparate locations, and the ability to extract data for data analytics and machine learning.
In September 2018, of the total 18 analysts covering Quest Diagnostics (DGX), ten analysts have given Quest stock a “buy” or higher rating, and eight analysts have given Quest a “hold” rating. The mean rating for Quest stock is 2.22 with a target price of $116.86 implying an upside potential of 9% over Quest’s closing price of $107.22 on September 18, 2018.
Quest Diagnostics (DGX) is a leading provider of diagnostic information services. Quest makes use of its database of clinical lab results to gain diagnostic insights that help to improve healthcare management. Quest’s diagnostics information services business (or DIS) provides data and insights based on routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing and other diagnostic information services.
So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.
Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.
To hear some politicians tell it, unfair trade and labor practices have been killing American factory jobs and punishing the U.S. economy for years — and 2018 is finally the year we fight back. As Michael Hicks and Srikant Devaraj of Ball State noted in a research report entitled “The Myth and Reality of Manufacturing in America,” productivity in the sector has exploded in the last decade or two thanks to technological innovations, with automation chief among them. For example, if productivity had remained constant from the year 2000 to 2010, U.S. manufacturers would have employed 20.9 million workers in 2010 to achieve that year’s total output, rather than just 12.1 million.
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.